Evidence map›Paper›PMID 28733795›Full record

Trial reportInternational journal of clinical oncology2017

Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Yosuke Yasuda, Kazutaka Saito, Takeshi Yuasa, Sho Uehara, Naoko Kawamura, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Shinya Yamamoto, Tetsuo Okuno and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yosuke YasudaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Kazutaka SaitoDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan. kz-saito.uro@tmd.ac.jp.
Takeshi YuasaDepartment of Urology, Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan.
Sho UeharaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Naoko KawamuraDepartment of Urology, JA Toride Medical Center, Ibaraki, Japan.
Minato YokoyamaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Junichiro IshiokaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Yoh MatsuokaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Shinya YamamotoDepartment of Urology, Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuo OkunoDepartment of Urology, JA Toride Medical Center, Ibaraki, Japan.
Junji YoneseDepartment of Urology, Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazunori KiharaDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Yasuhisa FujiiDepartment of Urology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.
Tokyo Medical and Dental University · JPJapanese Foundation For Cancer Research · JPJA Toride Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPretreatment C-reactive protein (CRP) has been shown to be an independent prognostic factor for metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). We further evaluated the early response of CRP after the initiation of TKIs.

methodsA total of 103 patients (80 men and 23 women) were treated with TKIs for mRCC from 2008-2013. Patients were divided into three groups according to their early CRP kinetics-patients whose baseline CRP levels were <10 mg/L (non-elevated), patients whose baseline CRP levels were ≥10 mg/L and had decreased by >20% at 4 weeks after the initiation of TKIs (early CRP responder), and the remaining patients (non-early CRP responder). The endpoints were progression-free survival (PFS) and overall survival (OS).

resultsThe median follow-up period was 21 (interquartile range 10-34) months. The numbers of patients classified as non-elevated, early CRP responder, and non-early CRP responder were 62, 19, and 22, respectively. The 1-year PFS rates of patients in the non-elevated, early CRP responder, and non-early CRP responder groups were 50, 23, and 9.7%, respectively (p < 0.001). The 1-year OS rates of patients in these three groups were 79, 62, and 36%, respectively (p < 0.001). In multivariate analysis, the early CRP kinetics assessment was a significant independent factor for PFS and OS.

conclusionsEarly CRP response at 4 weeks is predictive of survival for patients with mRCC treated with TKI.

Indexed as

AgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellC-Reactive ProteinDisease-Free SurvivalFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsPrognosisProtein Kinase InhibitorsAntineoplastic AgentsBiomarkers, TumorC-Reactive ProteinIndolesNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsPyrrolesSorafenibSunitinibC-reactive proteinMetastatic renal cell carcinomaTyrosine kinase inhibitors

Identifiers

PMID28733795
OpenAlexW2738751060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.